Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

NCT ID: NCT05133804

Last Updated: 2025-03-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-01
• Study Completion Date: 2025-12-01

Brief Summary

Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.

Detailed Description

Posttraumatic stress disorder (PTSD) is a highly impairing psychiatric disorder, characterized by re-experiencing, avoidance behaviour, emotional numbing, and hyperarousal after traumatic exposure. Current treatments mainly focus on non-cognitive symptoms and are only partially effective: one third of PTSD patients will find symptoms to be chronic and progressive; highly impacting daily function and quality of life. Arising evidence suggests a correlation between impaired attention, sensory dysfunction, and PTSD symptoms. Thus, the importance of combined treatment, focused on concentration difficulties as often found PTSD, has been suggested. Two suggested leads are reboxetine and methylphenidate.

Hypothesising that impaired attentional and sensory processing induces re-experiencing with avoidance and hyperarousal as coping strategies, the investigators aim to elucidate the neuro-dysregulation characteristics of each of the PTSD symptoms, with focus on attention, executive function and sensory processing, and relate to their implications on daily life function, following a novel combined treatment strategy of reboxetine and methylphenidate (Ritalin).

A case-control study will be conducted, including 53adult patients with PTSD and 53 matched healthy controls. First, a baseline measure will be performed amongst all participants to create a population profile. Then, patients will be randomised into an active treatment group (n=27) and a placebo group (n=26) for a double-blind randomized controlled trial, investigating the effect of a 3-week treatment with reboxetine 4mg per day and a one-week addition of Ritalin 10mg twice a day.

This research will include established and innovative neurophysiological measures and questionnaires. A PTSD symptom profile will be created combining the Clinician-Administered Posttraumatic Stress Disorder Scale and Posttraumatic Stress Disorder Symptom Scale. Brain activity will be measured using functional near-infrared spectroscopy (fNIR) or electroencephalography, with the Auditory Sustained Attention Test (ASAT) and Electrodermal Activity (EDA). Together with the Conners' Adult Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale - Short Version, the ASAT and EDA will create an attentional profile. Furthermore, a sensory profile consisting of the Adolescent/Adult Sensory Profile Questionnaire, and an executive function profile measured with the Behavior Rating Inventory of Executive Function will be created. Finally, in order to relate to individual experiences in real-life context, this research measures activities through the Daily Living Questionnaire and quality of life with the World Health Organization Quality of Life Instrument.

Using a translational research paradigm, this research is one of the first to investigate neuro-dysregulation in PTSD with a focus on sensory processing and executive function, with emphasis on attention and behaviour. It is also the first research to integrate the fNIR with the ASAT and EDA, thus contributing to the technological advancing of clinical research. This research will gather innovative data that may offer new explanations of PTSD symptoms and allow for further development of treatment interventions needed to reduce the burden of disease and optimise quality of life.

Conditions

Posttraumatic Stress Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Treatment with Reboxetine and Methylphenidate

During the first 3 weeks of the study, subjects in the active treatment group will take reboxetine at a dose of 4mgper day, with the instructions to start at 2mg per day for 3 days and then increase the dosage to 4mg per day for 26 days, i.e. until completion of the study.

On day 22 of the study, the patients will take the first dosage of10mg Ritalin or a placebo, and remain in the clinic for 2 hours to guard safety and guidance during possible occurrence of side effects such as anxiety, palpitations, etc. During the observation time in the clinic, 6 Ritalin IR 10mg and 3 Reboxetine 4mg pills will be handed out to the participants. These pills will be taken at the responsibility of the subject at8:00 AM (Ritalin and Reboxetine) and at noon (Ritalin only) at the following three days.

Group Type: EXPERIMENTAL

Methylphenidate

Intervention Type: DRUG

Ritalin 10mg

Reboxetine

Intervention Type: DRUG

Reboxetine 4mg

Treatment with Placebo

The patients will take placebos according to the medication schedule of the treatment group.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo matched to Reboxetine

Placebo

Intervention Type: DRUG

Placebo matched to Ritalin

Interventions

Methylphenidate

Ritalin 10mg

Intervention Type: DRUG

Reboxetine

Reboxetine 4mg

Intervention Type: DRUG

Placebo

Placebo matched to Reboxetine

Intervention Type: DRUG

Placebo

Placebo matched to Ritalin

Intervention Type: DRUG

Other Intervention Names

Ritalin; Placebo matched to Reboxetine; Placebo matched to Ritalin

Eligibility Criteria

Inclusion Criteria

• diagnosed with PTSD according to DSM-IV or DSM-5 criteria
• current treatment at the outpatient facilities of Lev HaSharon Netanya Adult Clin
• age between 20 and 60 years
• PTSD diagnosis at least one month prior to study inclusion
• no present-day re-exposure to the traumatic event
• any psychotropic drug therapy that is being administered must be at a fixed dose for at least one month prior to the study conductance

Exclusion Criteria

1. comorbid major psychiatric disorder, e.g. psychotic disorder, unipolar or bipolar disorder, borderline personality disorder, or active suicidal ideation,

2. ADHD diagnosis,

3. significant or severe systematic disease that limits normal activity, e.g. autoimmune disease, AIDS or renal failure,

4. cardiovascular disease, e.g. hypertension, atrioventricular (AV) block, bradycardia, or conduction disorder,

5. severe disease that is a threat to life, e.g. acute myocardial infarction, respiratory failure, or cancer,

6. nervous system impairment, e.g. multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, or stroke,

7. previous or current severe traumatic brain injury,

8. glaucoma,

9. impaired hearing,

10. pregnancy or breastfeeding during study inclusion,

11. active substance dependency including regular use of medical cannabis,

12. use of steroid medication in the two months prior to study conductance,

13. use of medication that may affect the function of the central nervous system,

14. failure to complete all research steps

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Haifa

OTHER

Sponsor Role: lead

Responsible Party

Avi Avital

Professor at Department of Occupational Therapy; Head of Behavioral Neurobiology lab

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Avi Avital, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Haifa

Batya Engel-Yeger, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Haifa

Inbal Brenner, MD

Role: PRINCIPAL_INVESTIGATOR

Lev HaSharon Mental Health Center

Tsipi Milman, MD

Role: PRINCIPAL_INVESTIGATOR

Emek Medical Center

Locations

Emek Medical Center

Afula, , Israel

Site Status: RECRUITING

University of Haifa

Haifa, , Israel

Site Status: RECRUITING

Lev HaSharon Mental Health Center

Netanya, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Avi Avital, PhD

Role: CONTACT

avitalavi@hotmail.com

+972-4-8420-364

Facility Contacts

Tsipi Milman, MD

Role: primary

tsipimi@clalit.org.il

Avi Avital, PhD

Role: primary

avitalavi@hotmail.com

+972-4-8420-364

Batya Engel-Yeger, PhD

Role: backup

bengel@univ.haifa.ac.il

+972-4-828-8387

Inbal Brenner, MD

Role: primary

inbalbrenner@gmail.com

+972 9 8981111

References

Aga-Mizrachi S, Cymerblit-Sabba A, Gurman O, Balan A, Shwam G, Deshe R, Miller L, Gorodetsky N, Heinrich N, Tzezana O, Zubedat S, Grinstein D, Avital A. Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model. Transl Psychiatry. 2014 Sep 23;4(9):e447. doi: 10.1038/tp.2014.82.

Reference Type: BACKGROUND

PMID: 25247592 (View on PubMed)

McAllister TW, Zafonte R, Jain S, Flashman LA, George MS, Grant GA, He F, Lohr JB, Andaluz N, Summerall L, Paulus MP, Raman R, Stein MB. Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Neuropsychopharmacology. 2016 Apr;41(5):1191-8. doi: 10.1038/npp.2015.282. Epub 2015 Sep 11.

Reference Type: BACKGROUND

PMID: 26361060 (View on PubMed)

Other Identifiers

LH9/2019

Identifier Type: -

Identifier Source: org_study_id